Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

[at noodls] – Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease Results to be Presented at LDN WORLD Symposium in … more

View todays social media effects on FOLD

View the latest stocks trending across Twitter. Click to view dashboard

See who Amicus is hiring next, click here to view